Participated · Series A · Jun 2026

Bionyra is advancing a pipeline of next-generation mono- and multispecific antibodies engineered with half-life extension to target immune pathways in diseases with high unmet need. Lead programs include BYN-002, a TL1A monoclonal antibody in a fully enrolled Phase 1 in healthy subjects; BYN-003, a TL1A*IL-23p19 bispecific that entered Phase 1 in April; and BYN-001, an IL-25 monoclonal antibody in IND-stage for atopic dermatitis and type 2 inflammation. The company holds exclusive global rights to these assets outside Greater China through licenses from TrueLab Biopharmaceutical and NovaRock Biotherapeutics, and is progressing additional preclinical assets. Bionyra was co-founded and seed financed by Sofinnova Partners and is led by CEO Frédéric Marrache, a former Sanofi R&D executive with experience in immunology and inflammation. The company plans to use its Series A proceeds to advance clinical development and rapidly generate clinical validation in dermatology and inflammatory bowel disease.

Participated · Series B · May 2026

NUCLIDIUM focuses on copper isotopes for radiotheranostics, using copper-61 for imaging and copper-67 for therapeutic applications. Its lead programs are NU101 for metastatic castration-resistant prostate cancer and NU201 for metastatic breast cancer, both slated to begin therapeutic phase 1/2a trials this year. The company reports that diagnostic phase 1/2 trial data to date show strong momentum, according to CEO and co-founder Leila Jaafar. NUCLIDIUM operates sites in Basel and Munich and is currently in the clinical development phase. It plans to expand its international production and manufacturing network for diagnostics and therapy and to develop new target structures in preclinical work to address additional solid tumor types.

Participated · Series A · Apr 2026

Generare builds a platform combining high-throughput cloning and sequencing to identify, express, and characterise novel small molecules from microbial genomes, generating structured data on their properties. The company is focused on expanding the accessible chemical space for drug discovery by creating a large-scale dataset of previously unexplored molecular diversity. Founded in 2023, Generare reports growing adoption of its platform among pharmaceutical and research organisations, with discovered molecules entering early-stage drug development. Its immediate plans include expanding its compound library, scaling its discovery capabilities, and hiring across a multidisciplinary team to meet demand. Financially, the company recently secured €20 million in a Series A to fund those growth initiatives.

Participated · Equity · Sep 2025

Founded in 2015, Belgium-headquartered Sunrise Group pairs FDA-cleared sleep-diagnostic hardware—most notably its mandibular movement sensor—with a full-stack software platform to power Dreem Health, its U.S. digital sleep clinic. Patients connect online with licensed sleep specialists who diagnose and treat conditions such as sleep apnea and insomnia entirely from home and with insurance coverage. Sunrise has regulatory clearances in all 50 states, contracts with payors that collectively insure more than 170 million Americans, and a clinical network exceeding 500 referring providers. The company operates with a team of 80+ clinicians, engineers, and researchers and positions its integrated tech-and-care model as a scalable answer to the severe shortage of sleep physicians. Revenue figures were not disclosed, but the firm secured a $29 million capital infusion to fund nationwide expansion and next-generation hardware and software development. Future plans include enlarging clinical services, accelerating U.S. market penetration, and continuing R&D on detection, monitoring, and treatment technologies for a broad range of sleep disorders.

Led · Seed · Nov 2024

BiocSol, a UCLouvain spin-off based in Louvain-la-Neuve, develops microbial-based biopesticides with increased stability and efficiency to help farmers protect crops sustainably. The company leverages specific microbial substances to deliver reliable, affordable solutions for agricultural challenges such as mildew affecting row crops (potatoes), other vegetables and grapes. Led by CTO and founder Simon Caulier and CEO Denis Payen, BiocSol is focused on building its R&D platform to advance product candidates. The company plans to use the newly raised capital to support future development of that R&D platform. BiocSol's product strategy emphasizes improved stability and efficacy relative to existing biopesticide approaches. In November 2024 the company secured €5.2M in equity funding in a round led by Agri Investment Fund and VIVES Partners. BiocSol develops microbial-based biopesticides that provide biocontrol against crop pathogens, with its first products recently tested in real field conditions. The company harnesses specific microbial substances to create reliable, stable and cost-effective biosolutions targeting issues such as mildew and emerging fungal and oomycete pathogens. With the new funding, BiocSol plans to expand its team, broaden its R&D pipeline and kickstart regulatory processes for biofungicides. Management also intends to increase production capacity and optimize quality and efficiency processes to meet demand. The company says its mission is to deliver more sustainable and efficient agricultural solutions to farmers worldwide. BiocSol aims to attract a total of €10M by year-end through additional non-dilutive and equity financing.